Beam Therapeutics (BEAM) Cash & Equivalents (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Cash & Equivalents data on file, last reported at $288.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 45.39% year-over-year to $288.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $288.3 million (down 45.39% YoY) and the FY2025 annual result came in at $294.9 million, up 4.6% from the prior year.
• Cash & Equivalents retreated to $288.3 million in Q1 2026 per BEAM's latest filing, from $294.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $527.9 million in Q1 2025 and bottomed at $156.5 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $282.0 million (2024), against an average of $281.5 million.
• Peak annual rise in Cash & Equivalents reached 205.24% in 2022, while the deepest fall reached 74.43% in 2022.
• Tracing BEAM's Cash & Equivalents over 5 years: stood at $232.8 million in 2022, then jumped by 87.27% to $435.9 million in 2023, then tumbled by 35.31% to $282.0 million in 2024, then rose by 4.6% to $294.9 million in 2025, then slipped by 2.26% to $288.3 million in 2026.
• Per Business Quant, the three latest BEAM Cash & Equivalents figures stand at $288.3 million (Q1 2026), $294.9 million (Q4 2025), and $268.0 million (Q3 2025).

Peer Comparison